JP2006504721A5 - - Google Patents

Download PDF

Info

Publication number
JP2006504721A5
JP2006504721A5 JP2004542491A JP2004542491A JP2006504721A5 JP 2006504721 A5 JP2006504721 A5 JP 2006504721A5 JP 2004542491 A JP2004542491 A JP 2004542491A JP 2004542491 A JP2004542491 A JP 2004542491A JP 2006504721 A5 JP2006504721 A5 JP 2006504721A5
Authority
JP
Japan
Prior art keywords
bcrp
camptothecin
anticancer agents
resistance
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004542491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006504721A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/011271 external-priority patent/WO2004032925A1/en
Publication of JP2006504721A publication Critical patent/JP2006504721A/ja
Publication of JP2006504721A5 publication Critical patent/JP2006504721A5/ja
Pending legal-status Critical Current

Links

JP2004542491A 2002-10-11 2003-10-10 治療剤に対する乳癌耐性タンパク質（ｂｃｒｐ）−介在耐性を阻害するためのイマチニブ（グリベック、ｓｔｉ−５７１）の使用 Pending JP2006504721A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41791502P 2002-10-11 2002-10-11
PCT/EP2003/011271 WO2004032925A1 (en) 2002-10-11 2003-10-10 Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents

Publications (2)

Publication Number Publication Date
JP2006504721A JP2006504721A (ja) 2006-02-09
JP2006504721A5 true JP2006504721A5 (https=) 2006-11-24

Family

ID=32094119

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004542491A Pending JP2006504721A (ja) 2002-10-11 2003-10-10 治療剤に対する乳癌耐性タンパク質（ｂｃｒｐ）−介在耐性を阻害するためのイマチニブ（グリベック、ｓｔｉ−５７１）の使用

Country Status (4)

Country Link
US (1) US7879868B2 (https=)
JP (1) JP2006504721A (https=)
AU (1) AU2003273986A1 (https=)
WO (1) WO2004032925A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1768672A2 (en) * 2004-07-01 2007-04-04 The Netherlands Cancer Institute Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-ý4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl¨-benzamide
DE602006015994D1 (de) * 2005-06-23 2010-09-16 Novartis Ag Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
EP2036561B1 (en) * 2006-06-22 2017-05-10 Nippon Chemiphar Co., Ltd. Agent for overcoming resistance to anti-cancer agent
WO2008098178A2 (en) * 2007-02-09 2008-08-14 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
CA2738807A1 (en) * 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
WO2011130918A1 (zh) 2010-04-23 2011-10-27 上海百灵医药科技有限公司 一种伊马替尼的合成方法
JP6013359B2 (ja) * 2010-12-17 2016-10-25 ノバルティス アーゲー 組合せ
MX352749B (es) 2011-11-01 2017-12-06 Modgene Llc Composiciones y metodos para la reduccion de la carga amiloide-beta.
WO2016164593A1 (en) * 2015-04-07 2016-10-13 President And Fellows Of Harvard College Compositions and methods for modulating hydroxylation of acc2 by phd3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (https=) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors

Similar Documents

Publication Publication Date Title
You et al. Topoisomerase inhibitors and targeted delivery in cancer therapy
Verschraegen et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor
O’Leary et al. Camptothecins: a review of their development and schedules of administration
Kehrer et al. Modulation of camptothecin analogs in the treatment of cancer: a review
Zunino et al. Current status and perspectives in the development of camptothecins
Basili et al. Novel camptothecin derivatives as topoisomerase I inhibitors
JP2006504721A5 (https=)
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
RU2018102080A (ru) Комбинированная терапия противоопухолевым алкалоидом
JP2006503919A5 (https=)
JP2011503071A5 (ja) ヨードニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる卵巣がんの治療
WO2007117466A3 (en) Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
BG108072A (en) The use of epothilone derivatives for the treatment of refractory tumors
WO2006052767A3 (en) Compositions and methods for stabilizing liposomal camptothecin formulations
JP2003525234A (ja) カンプトテシン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
WO2007059106A3 (en) Administration of mntor inhibitor to treat patients with cancer
JP2002507571A (ja) アントラサイクリン誘導体とカンプトテシン誘導体の相乗組合せを含有する抗腫瘍組成物
UA101339C2 (ru) Лечение заболеваний толстой кишки или предотвращение карциномы толстого кишечника с помощью имидазохинолиновых производных
JP2003525255A (ja) ファルネシルタンパク質トランスフェラーゼ阻害剤とさらなる抗癌剤との組み合わせ剤
JP2004502789A5 (https=)
Gelderblom et al. Oral topoisomerase 1 inhibitors in adult patients: present and future
Legarza et al. Novel camptothecin derivatives
ATE523200T1 (de) Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel
WO2012058666A3 (en) Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy